Product Description
A 5-aminoimidazole-4-carboxamide (AICA) riboside, a purine nucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis.
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ADVANCELL
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Myocardial Infarction|Pulmonary Infarction|Ventricular Dysfunction, Left|Stroke|Coronary Artery Disease
Phase 2: Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Febrile Neutropenia|Acute Monocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Shoulder Pain|Musculoskeletal Pain |
2018-11-30 |
|
| 2012-003120-21 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome |
2015-04-15 |
|
| Acadesine | P2 |
Terminated |
Febrile Neutropenia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome |
2013-06-01 |
|
| ATH001-CLN01 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2010-12-01 |